Next Article in Journal
Behavior of Regular Insulin in a Parenteral Nutrition Admixture: Validation of an LC/MS-MS Assay and the In Vitro Evaluation of Insulin Glycation
Next Article in Special Issue
Development of an LNP-Encapsulated mRNA-RBD Vaccine against SARS-CoV-2 and Its Variants
Previous Article in Journal
Micro- and Nano-Systems Developed for Tolcapone in Parkinson’s Disease
Previous Article in Special Issue
Regeneration of Articular Cartilage Using Membranes of Polyester Scaffolds in a Rabbit Model
 
 
Article

Development of Jelly Loaded with Nanogel Containing Natural L-Dopa from Mucuna pruriens Seed Extract for Neuroprotection in Parkinson’s Disease

1
Department of Pharmaceutical Sciences, Faculty of Pharmacy, Chiang Mai University, Mueang, Chiang Mai 50200, Thailand
2
Research Center of Pharmaceutical Nanotechnology, Faculty of Pharmacy, Chiang Mai University, Mueang, Chiang Mai 50200, Thailand
3
Department of Pharmacognosy, Faculty of Pharmacy, Srinakharinwirot University, Ongkharak, Nahonnayok 26120, Thailand
4
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Srinakharinwirot University, Ongkharak, Nahonnayok 26120, Thailand
5
Department of Chemistry and Center of Excellence for Innovation in Chemistry, Faculty of Science, Kasetsart University, Chatuchak, Bangkok 10900, Thailand
6
Department of Pharmaceutical Technology, Faculty of Pharmacy, Srinakharinwirot University, Ongkharak, Nakhonnayok 26120, Thailand
7
Department of Industrial Pharmacy, School of Pharmacy, Eastern Asia University, Thanyaburi, Pathum Thani 12110, Thailand
*
Author to whom correspondence should be addressed.
Academic Editors: Bogdan Stefan Vasile and Ionela Andreea Neacsu
Pharmaceutics 2022, 14(5), 1079; https://doi.org/10.3390/pharmaceutics14051079
Received: 12 April 2022 / Revised: 14 May 2022 / Accepted: 16 May 2022 / Published: 17 May 2022
The first line therapy of patients with Parkinson’s disease, a neurodegenerative disorder caused by the degeneration of dopaminergic neurons, is levodopa (L-dopa) given orally. Recently, the presence of natural L-dopa in the seed of Mucuna pruriens, a tropical legume in the Fabaceae family, was reported and it showed superior efficiency compared with synthetic L-dopa. Therefore, this study aimed to examine the phytochemical compounds, particularly for natural L-dopa, in M. pruriens seed extract and subsequently prepare a nanogel containing the extract prior to incorporation into a jelly formulation for use as a functional food in elderly patients with Parkinson’s disease. The results show that M. pruriens seed extract contains phenolic compounds, flavonoids, tannins, alkaloids, terpenoids, and saponins. The quantitative analysis performed by the HPLC method revealed that spray-dried M. pruriens seed extract contained 5.59 ± 0.21% L-dopa. M. pruriens seed extract possesses a ferric-reducing antioxidant power and shows free-radical scavenging activity, determined by DPPH and ABTS methods, suggesting a distinctive antioxidant ability of the extract. M. pruriens seed extract at 10 ng/mL did not show cytotoxicity against a neuronal cell line (SH-SY5Y cells), kidney cells (HEK293 cells), or Caco-2 cells. Nanogel of M. pruriens seed extract prepared by ionic gelation had the hydrodynamic diameter, polydispersity index and zeta potential value of 384.53 ± 11.24 nm, 0.38 ± 0.05, and −11.23 ± 1.15 mV, respectively. The transepithelial transport of L-dopa in M. pruriens seed-extract nanogel through Caco-2 cells was measured. Nanogel containing M. pruriens seed extract at the concentration of 10 ng/mL exhibited neuroprotective activity. A jelly formulation containing M. pruriens seed-extract nanogel was successfully developed. The prepared jelly exhibited the acceptable physical and microbiological stabilities upon 6 months of the stability test. The half-life of natural L-dopa in jelly were 3.2, 0.9, and 0.6 years for storage conditions at 4, 30, and 40 °C, respectively, indicating the thermal degradation of natural L-dopa. The prepared jelly containing natural L-dopa from M. pruriens seed extract with the prominent antioxidant activity is a promising option for elderly patients suffering from Parkinson’s disease. View Full-Text
Keywords: M. pruriens seed; functional food; Parkinson’s disease; levodopa; nanogel M. pruriens seed; functional food; Parkinson’s disease; levodopa; nanogel
Show Figures

Graphical abstract

MDPI and ACS Style

Chittasupho, C.; Tadtong, S.; Vorarat, S.; Imaram, W.; Athikomkulchai, S.; Samee, W.; Sareedenchai, V.; Thongnopkoon, T.; Okonogi, S.; Kamkaen, N. Development of Jelly Loaded with Nanogel Containing Natural L-Dopa from Mucuna pruriens Seed Extract for Neuroprotection in Parkinson’s Disease. Pharmaceutics 2022, 14, 1079. https://doi.org/10.3390/pharmaceutics14051079

AMA Style

Chittasupho C, Tadtong S, Vorarat S, Imaram W, Athikomkulchai S, Samee W, Sareedenchai V, Thongnopkoon T, Okonogi S, Kamkaen N. Development of Jelly Loaded with Nanogel Containing Natural L-Dopa from Mucuna pruriens Seed Extract for Neuroprotection in Parkinson’s Disease. Pharmaceutics. 2022; 14(5):1079. https://doi.org/10.3390/pharmaceutics14051079

Chicago/Turabian Style

Chittasupho, Chuda, Sarin Tadtong, Suwanna Vorarat, Witcha Imaram, Sirivan Athikomkulchai, Weerasak Samee, Vipaporn Sareedenchai, Thanu Thongnopkoon, Siriporn Okonogi, and Narisa Kamkaen. 2022. "Development of Jelly Loaded with Nanogel Containing Natural L-Dopa from Mucuna pruriens Seed Extract for Neuroprotection in Parkinson’s Disease" Pharmaceutics 14, no. 5: 1079. https://doi.org/10.3390/pharmaceutics14051079

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop